357 related articles for article (PubMed ID: 23652861)
1. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Park SH; Rha SW; Choi CU; Kim EJ; Oh DJ; Cho YH; Choi WG; Lee SJ; Kim YH; Choi SH; Kim WH; Kim KC; Cho JH; Kim JH; Kim SM; Bae JH; Bong JM; Kang WY; Baek JY; Seo JB; Chung WY; Park MW; Her SH; Suh J; Kim MW; Kim YJ; Choi HJ; Soh JW;
Trials; 2014 Sep; 15():355. PubMed ID: 25208688
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.
Iida O; Nanto S; Uematsu M; Morozumi T; Kitakaze M; Nagata S
J Vasc Surg; 2008 Jul; 48(1):144-9. PubMed ID: 18482817
[TBL] [Abstract][Full Text] [Related]
5. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Soga Y; Hamasaki T; Edahiro R; Iida O; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Aodo K;
J Endovasc Ther; 2018 Jun; 25(3):306-312. PubMed ID: 29706129
[TBL] [Abstract][Full Text] [Related]
6. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
[TBL] [Abstract][Full Text] [Related]
7. Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Miura T; Miyashita Y; Soga Y; Hozawa K; Doijiri T; Ikeda U; Kuwahara K;
Circ Cardiovasc Interv; 2018 Aug; 11(8):e006564. PubMed ID: 30354784
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
[TBL] [Abstract][Full Text] [Related]
9. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial.
Rastan A; Krankenberg H; Baumgartner I; Blessing E; Müller-Hülsbeck S; Pilger E; Scheinert D; Lammer J; Gißler M; Noory E; Neumann FJ; Zeller T
Circulation; 2013 Jun; 127(25):2535-41. PubMed ID: 23694965
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
[TBL] [Abstract][Full Text] [Related]
11. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.
Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Tanaka M; Kamoi D; Kawamura Y; Yamada S; Hayashi M; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
Clin Ther; 2010 Jan; 32(1):24-33. PubMed ID: 20171408
[TBL] [Abstract][Full Text] [Related]
13. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions.
Lichtenberg M; Kolks O; Hailer B; Stahlhoff WF; Tiefenbacher C; Nolte-Ernsting C; Arjumand J; Wittenberg G
J Endovasc Ther; 2014 Jun; 21(3):373-80. PubMed ID: 24915584
[TBL] [Abstract][Full Text] [Related]
14. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.
Laird JR; Katzen BT; Scheinert D; Lammer J; Carpenter J; Buchbinder M; Dave R; Ansel G; Lansky A; Cristea E; Collins TJ; Goldstein J; Jaff MR;
Circ Cardiovasc Interv; 2010 Jun; 3(3):267-76. PubMed ID: 20484101
[TBL] [Abstract][Full Text] [Related]
15. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center.
Shammas NW; Shammas GA; Helou TJ; Voelliger CM; Mrad L; Jerin M
Cardiovasc Revasc Med; 2012; 13(4):224-7. PubMed ID: 22575073
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
[TBL] [Abstract][Full Text] [Related]
17. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
[TBL] [Abstract][Full Text] [Related]
18. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
[TBL] [Abstract][Full Text] [Related]
19. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
Soga Y; Iida O; Kawasaki D; Hirano K; Yamaoka T; Suzuki K
Eur J Vasc Endovasc Surg; 2012 Dec; 44(6):577-81. PubMed ID: 23107298
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
